Need Help? Contact Us.

Enquire now


Product Description

The TGS COVID-19 IgG test is a chemiluminescent two-step sandwich capture immunoassay (CLIA), for use on IDS-iSYS Multi-Discipline Automated System, for QUANTITATIVE determination of specific IgG class antibodies directed against the SARS-CoV-2 Spike and Nucleocapsid antigens in samples of human serum or plasma (K3-EDTA, sodium citrate, sodium heparin).

This assay is used as a diagnostic aid when assessing immunity status of patients related to COVID-19.

  • Employs Spike (S1) and Nucleocapsid antigens for optimal detection, including no observed cross reactivity to other coronavirus strains
  • QUANTITATIVE test for the assessment of IgG antibodies against SARS-CoV-2
  • Excellent sensitivity and specificity
  • Suitable for use with human serum or plasma
  • Convenient reagents handling, with ready to use reagents combined with 60 days on-board storage
    1. Li, F., Li, W., Farzan, M., & Harrison, S. (2005). Structure of SARS coronavirus spike receptor-binding domain complexed with its 10.2210/pdb2ajf/pdb 3. Ou, X., Liu, Y., Lei, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620 (2020). View here
    2. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods [published online ahead of print, 2020 Feb 27]. Acta Pharm Sin B. 2020;10(5):766-788. doi:10.1016/j.apsb.2020.02.008

Add to Enquiry Basket



Related Products

Assays Certification Platform Clinical Area Portfolio RUO/IVD
TGS COVID-19 IgM CE Marked i10iSYS RespiratoryVaccine Preventable Infectious Diseases IVD
This site is registered on as a development site.